|
2011
|
Invention
|
Bifeprunox mesylate maintenance dose compositions and methods for using the same.
The present di... |
|
|
Invention
|
5-aryl-4,5-dihydro-(1h)-pyrazolines as cannabinoid cb1 receptor agonists.
The invention is direc... |
|
2010
|
Invention
|
Bifeprunox doses for treating schizophrenia.
The present disclosure is directed to compositions,... |
|
|
Invention
|
Oral solid solution formulation of a poorly water-soluble active substance.
An immediate release... |
|
|
Invention
|
1 receptor antagonists. 2 receptor subtype selectivity, to methods for the preparation of these ... |
|
|
Invention
|
Process for the preparation of 3-amino-8-(1-piperazinyl)-2h-1-benzopyran-2-one and salts and solv... |
|
|
Invention
|
Methods of making and using therapeutically active thiophenepyrimidinone compounds.
Thiophenepry... |
|
|
Invention
|
Muscarinic agonists to treat impulse control disorders.
The invention relates to a novel use of ... |
|
2009
|
Invention
|
Method of treatment using eprosartan.
The disclosed invention relates to a method of treatment o... |
|
|
Invention
|
Compositions, kits and methods for a titration schedule for pardoprunox compounds.
The present i... |
|
2008
|
Invention
|
Phenylpiperazine. 2 receptor and/or the serotonin reuptake site, and the ability to treat conditi... |
|
|
Invention
|
5-aryl-4,5-dihydro-(1h)-pyrazolines as cannabinoid cb1 receptor agonists. 1 receptors are involve... |
|
|
Invention
|
1 antagnistic activity. 4 have the meanings given in the specification.
|
|
|
Invention
|
Sildenafil n-oxide as prodrug.
Embodiments of the present invention relate to a compound of form... |
|
|
Invention
|
N-oxides of venlafaxine and o-desmethylvenlafaxine as prodrugs. The invention concerns venlafaxin... |
|
|
Invention
|
Sildenafil n-oxide as prodrug. The invention concerns sildenafil N-oxide as prodrug, to pharmaceu... |
|
|
Invention
|
4,5-dihydro-(1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators. This invention rela... |
|
|
Invention
|
1 receptor modulators. 1 receptor modulators, to pharmaceutical compositions comprising these com... |
|
|
Invention
|
Pharmaceutical tablet |
|
|
Invention
|
Heterocyclic compounds with affinity to muscarinic receptors. The present invention relates to he... |
|
|
Invention
|
Use of 5-ht6 antagonists to prevent relapse into addiction. The invention relates to a novel use ... |
|
|
Invention
|
Use of 5-ht6 antagonists to prevent relapse into addiction.
A novel use of compounds and pharmac... |
|
|
Invention
|
Compounds with a combination of cannabinoid-cb1 antagonism and serotonin reuptake inhibition. Thi... |
|
2007
|
Invention
|
Therapeutically active thiophenepyrimidinone compounds and their use.
Thiopheneprymidinone compo... |
|
|
Invention
|
Compounds with a combination of cannabinoid-cb1 antagonism and acetylcholinesterase inhibition. T... |
|
|
Invention
|
Selective inhibitors of neurotensin degrading enzymes. This invention concerns selective inhibito... |
|
|
Invention
|
Selective inhibitors of neurotensin degrading enzymes.
Embodiments of this invention relate to c... |
|
|
Invention
|
Micellar nanoparticles of chemical substances. The present invention relates to a thermostable so... |
|
|
Invention
|
Novel human enzymes of the metalloprotease family.
This invention relates to newly identified po... |
|
|
Invention
|
Sulfonylpyrazoline carboxamidine derivatives as 5-ht6 antagonists. This invention concerns sulfon... |
|
|
Invention
|
Compositions, kits and methods for administering a titration schedule comprising bifeprunox compo... |
|
|
Invention
|
Titration schedule for bifeprunox for treating schizophrenia and kits for use therein. The presen... |
|
|
Invention
|
Bifeprunox doses for treating schizophrenia. The present disclosure is directed to a daily dose o... |
|
|
Invention
|
Azaindole derivatives with a combination of partial nicotinic acetylcholine receptor agonism and ... |
|
|
Invention
|
Oral pharmaceutical composition of a poorly water-soluble active agent.
The present invention re... |
|
|
Invention
|
Oral pharmaceutical composition of a poorly water-soluble active substance. Provided in the prese... |
|
|
Invention
|
Oral pharmaceutical composition of a poorly water-soluble active substance. The invention is rela... |
|
|
Invention
|
Combination preparations comprising slv308 and a l-dopa. The invention concerns the use of a comb... |
|
|
Invention
|
Combination preparations comprising bifeprunox and l-dopa. The invention concerns the use of a co... |
|
|
Invention
|
Oral pharmaceutical composition of poorly water-soluble active substance.
An oral composition of... |
|
|
Invention
|
Sulphur containing pyrazole derivatives as selective cannabinoid cb1 receptor antagonists. The pr... |
|
|
Invention
|
N-oxides of pyridylmethyl -piperazine and -piperidine derivatives.
N-oxides of certain pyridylm... |
|
|
Invention
|
N-oxides of pyridylmethylpiperazine and -piperidine derivatives. The invention concerns N-oxides ... |
|
|
Invention
|
Muscarinic agonists to treat impulse control disorders. The invention relates to a novel use of c... |
|
|
Invention
|
Bifeprunox mesylate maintenance dose compositions and methods for using the same. The present dis... |
|
|
Invention
|
Antibody to human enzymes of the metalloprotease family. This invention relates to newly identifi... |
|
|
Invention
|
1-antagonistic activity. The present invention relates to 1,2,4-tri-substituted imidazoline deriv... |
|
2006
|
Invention
|
4,5-dihydro-(1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators.
This invention is ... |
|
|
Invention
|
4,5-dihydro- (1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators. This invention is ... |
